6VY5 image
Entry Detail
PDB ID:
6VY5
Title:
Crystal structure of Nipah receptor binding protein head domain in complex with human neutralizing antibody HENV-26
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2020-02-25
Release Date:
2021-01-06
Method Details:
Experimental Method:
Resolution:
3.40 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.21
Space Group:
P 32 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:receptor binding protein
Chain IDs:C (auth: A)
Chain Length:433
Number of Molecules:1
Biological Source:Nipah henipavirus
Polymer Type:polypeptide(L)
Description:Anti-Hendra receptor binding protein antibody HENV-26 Fab heavy chain
Chain IDs:A (auth: H)
Chain Length:230
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Anti-Hendra receptor binding protein antibody HENV-26 Fab light chain
Chain IDs:B (auth: L)
Chain Length:214
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein.
Cell 183 1536 1550.e17 (2020)
PMID: 33306954 DOI: 10.1016/j.cell.2020.11.023

Abstact

Hendra (HeV) and Nipah (NiV) viruses are emerging zoonotic pathogens in the Henipavirus genus causing outbreaks of disease with very high case fatality rates. Here, we report the first naturally occurring human monoclonal antibodies (mAbs) against HeV receptor binding protein (RBP). All isolated mAbs neutralized HeV, and some also neutralized NiV. Epitope binning experiments identified five major antigenic sites on HeV-RBP. Animal studies demonstrated that the most potent cross-reactive neutralizing mAbs, HENV-26 and HENV-32, protected ferrets in lethal models of infection with NiV Bangladesh 3 days after exposure. We solved the crystal structures of mAb HENV-26 in complex with both HeV-RBP and NiV-RBP and of mAb HENV-32 in complex with HeV-RBP. The studies reveal diverse sites of vulnerability on RBP recognized by potent human mAbs that inhibit virus by multiple mechanisms. These studies identify promising prophylactic antibodies and define protective epitopes that can be used in rational vaccine design.

Legend

Protein

Chemical

Disease

Primary Citation of related structures